tetano
Editor, Senior Moderator
Microorganisms
. 2021 Dec 31;10(1):85.
doi: 10.3390/microorganisms10010085.
Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
George Krashias[SUP] 1 2 [/SUP], Elie Deeba[SUP] 2 [/SUP], Astero Constantinou[SUP] 2 [/SUP], Maria Hadjiagapiou[SUP] 1 3 [/SUP], Dana Koptides[SUP] 2 [/SUP], Jan Richter[SUP] 2 [/SUP], Christina Tryfonos[SUP] 2 [/SUP], Stavros Bashiardes[SUP] 2 [/SUP], Anastasia Lambrianides[SUP] 1 3 [/SUP], Maria A Loizidou[SUP] 1 4 [/SUP], Andreas Hadjisavvas[SUP] 1 4 [/SUP], Mihalis I Panayiotidis[SUP] 1 4 [/SUP], Christina Christodoulou[SUP] 1 2 [/SUP]
Affiliations
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit its second year and continues to damage lives and livelihoods across the globe. There continues to be a global effort to present serological data on SARS-CoV-2 antibodies in different individuals. As such, this study aimed to characterize the seroprevalence of SARS-CoV-2 antibodies in the Cypriot population for the first time since the pandemic started. Our results show that a majority of people infected with SARS-CoV-2 developed IgG antibodies against the virus, whether anti-NP, anti-S1RBD, or both, at least 20 days after their infection. Additionally, the percentage of people with at least one antibody against SARS-CoV-2 in the group of volunteers deemed SARS-CoV-2 negative via RT-PCR or who remain untested/undetermined (14.43%) is comparable to other reported percentages worldwide, ranging anywhere from 0.2% to 24%. We postulate that these percentages reflect the underreporting of true infections in the population, and also show the steady increase of herd immunity. Additionally, we showed a significantly marked decrease in anti-NP IgG antibodies in contrast to relatively stable levels of anti-S1RBD IgG antibodies in previously infected individuals across time.
Keywords: IgG antibody; SARS-CoV-2; Spike 1 receptor binding protein; nucleocapsid (N) protein; seroprevalence.
. 2021 Dec 31;10(1):85.
doi: 10.3390/microorganisms10010085.
Characterization of IgG Antibody Response against SARS-CoV-2 (COVID-19) in the Cypriot Population
George Krashias[SUP] 1 2 [/SUP], Elie Deeba[SUP] 2 [/SUP], Astero Constantinou[SUP] 2 [/SUP], Maria Hadjiagapiou[SUP] 1 3 [/SUP], Dana Koptides[SUP] 2 [/SUP], Jan Richter[SUP] 2 [/SUP], Christina Tryfonos[SUP] 2 [/SUP], Stavros Bashiardes[SUP] 2 [/SUP], Anastasia Lambrianides[SUP] 1 3 [/SUP], Maria A Loizidou[SUP] 1 4 [/SUP], Andreas Hadjisavvas[SUP] 1 4 [/SUP], Mihalis I Panayiotidis[SUP] 1 4 [/SUP], Christina Christodoulou[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35056533
- DOI: 10.3390/microorganisms10010085
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has hit its second year and continues to damage lives and livelihoods across the globe. There continues to be a global effort to present serological data on SARS-CoV-2 antibodies in different individuals. As such, this study aimed to characterize the seroprevalence of SARS-CoV-2 antibodies in the Cypriot population for the first time since the pandemic started. Our results show that a majority of people infected with SARS-CoV-2 developed IgG antibodies against the virus, whether anti-NP, anti-S1RBD, or both, at least 20 days after their infection. Additionally, the percentage of people with at least one antibody against SARS-CoV-2 in the group of volunteers deemed SARS-CoV-2 negative via RT-PCR or who remain untested/undetermined (14.43%) is comparable to other reported percentages worldwide, ranging anywhere from 0.2% to 24%. We postulate that these percentages reflect the underreporting of true infections in the population, and also show the steady increase of herd immunity. Additionally, we showed a significantly marked decrease in anti-NP IgG antibodies in contrast to relatively stable levels of anti-S1RBD IgG antibodies in previously infected individuals across time.
Keywords: IgG antibody; SARS-CoV-2; Spike 1 receptor binding protein; nucleocapsid (N) protein; seroprevalence.